Common drugs for type 2 diabetes and obesity do not increase breast cancer risk
Findings relieve concerns arising from clinical trials of liraglutide
2021-03-20
(Press-News.org) WASHINGTON--Commonly used medications for type 2 diabetes and obesity called glucagon like peptide-1 receptor agonists (GLP-1 RAs), are not associated with an increased risk of breast cancer, despite previous studies that suggested a possible link, according to a study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
"GLP-1RAs can be used as adjunct to diet and exercise in subjects with type 2 diabetes and those without type 2 diabetes and excess weight, without an increased risk of breast cancer or noncancerous masses in the breast," said lead researcher Giovana Fagundes Piccoli, M.D., of the Universidade Federal do Rio Grande do Sul in Brazil.
GLP-1 RAs have been shown to be effective in treating obesity and type 2 diabetes and in reducing heart disease. These drugs include albiglutide (Tanzeum); dulaglutide (Trulicity); exenatide (Byetta); extended-release exenatide (Bydureon); liraglutide (Victoza, Saxenda); lixisenatide (Adlyxin); and semaglutide (Ozempic, Rybelsus). In clinical trials of liraglutide, subjects treated with the active drug instead of a placebo had a higher number of breast cancers. The new study was designed to assess whether patients treated with GLP-1 RAs had a higher risk of breast cancer or benign growths in the breasts called neoplasms.
Piccoli reviewed 52 randomized controlled trials that compared GLP-1 RAs with non-GLP-1 RAs (either other diabetes or weight-loss drugs or placebos) in adults with overweight, obesity, prediabetes or diabetes. The studies had a minimum follow-up period of 24 weeks and reported at least one event of breast cancer or benign breast neoplasm. They included a total of 90,360 participants.
The analysis found treatment with GLP-1 RAs was not associated with increased rates of breast cancer or benign or premalignant breast neoplasms, compared to placebo or other diabetes or weight-loss drugs. Among 48,267 subjects treated with GLP-1 RAs, 130 developed breast cancer, compared to 107 of 40,755 controls.
INFORMATION:
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world's oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at http://www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.
ELSE PRESS RELEASES FROM THIS DATE:
2021-03-20
WASHINGTON--New genetic research suggests men can develop characteristics of polycystic ovary syndrome (PCOS)--a common metabolic and reproductive disorder that affects women. The study was presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
PCOS is a common disorder characterized by irregular menstrual periods, disruption of normal metabolism and elevated testosterone levels. PCOS affects up to 10% of all women of reproductive age. The disorder can lead to obesity, diabetes and cardiovascular disease, which are often life-long conditions.
Men who have genetic risk factors ...
2021-03-20
WASHINGTON--Addressing sleep symptoms during menopause may reduce susceptibility to weight gain, according to a small study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
"Our findings suggest that not only estrogen withdrawal but also sleep disturbances during menopause may contribute to changes in a woman's body that could predispose midlife women to weight gain," said lead researcher Leilah Grant, Ph.D., of Brigham and Women's Hospital in Boston, Mass. "Helping women sleep better during menopause may therefore reduce the chances ...
2021-03-20
WASHINGTON--Endogenous Cushing's syndrome, a rare hormonal disorder, is associated with a threefold increase in death, primarily due to cardiovascular disease and infection, according to a study whose results will be presented at ENDO 2021, the Endocrine Society's annual meeting.
The research, according to the study authors, is the largest systematic review and meta-analysis to date of studies of endogenous (meaning "inside your body") Cushing's syndrome. Whereas Cushing's syndrome most often results from external factors--taking cortisol-like medications such as prednisone--the endogenous type occurs when the body overproduces the hormone cortisol, affecting multiple bodily ...
2021-03-20
WASHINGTON--Two-thirds of patients with chronic endocrine health problems who need close monitoring say they would like to continue with telemedicine follow-up visits after the COVID-19 pandemic ends, according to a survey that will be presented virtually at ENDO 2021, the Endocrine Society's annual meeting. Three-quarters of providers also said they want to continue with telehealth after the pandemic.
"Endocrinology clinics have significant number of patients who need long-term close follow-up for medication adjustments, symptom checks and counseling," said lead researcher Maryam Nemati, M.D., of San Joaquin General Hospital in French Camp, Calif. "Our ...
2021-03-20
WASHINGTON--Treatment of hypothyroidism, which results from an underactive thyroid gland, should be individualized and consideration should be given to alternatives to the first-line therapy, including desiccated thyroid extract and combination therapy to replace the body's two main thyroid hormones, thyroxine (T4) and triiodothyronine (T3). Results of their new randomized clinical study are being presented at ENDO 2021, the Endocrine Society's annual meeting.
Combination therapy has been shown to be equally as effective as the standard treatment with levothyroxine alone, researchers say.
"There are now proven good treatment options for the more than one in 10 patients with hypothyroidism who continue to experience symptoms of fatigue, mental fogginess, weight ...
2021-03-20
WASHINGTON--An industry-supported study of an oral testosterone replacement therapy (TRT), testosterone undecanoate (TU, brand name Jatenzo) finds it is an effective, long-term treatment for men with low testosterone levels, with no evidence of liver toxicity. The findings are being presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
TST is currently available in multiple modes of administration, including implantable pellets, transdermal gels and intramuscular injections.
"For many men with low testosterone levels, an oral option is preferred to avoid issues associated with other ...
2021-03-20
WASHINGTON--Among women who develop diabetes during pregnancy, night owls have a higher risk of complications for mother and baby than early birds do, according to a study whose results will be presented at ENDO 2021, the Endocrine Society's annual meeting.
Compared with other pregnant women with gestational diabetes, those with a preference for evening activity had three times higher the chance of having preeclampsia, which is pregnancy-induced high blood pressure, and four times the rate of their newborns being treated in a neonatal intensive care unit, the study investigators reported.
These findings suggest a ...
2021-03-20
WASHINGTON--Children with achondroplasia, the most common form of disproportionate short stature, grow taller with trends in improved body proportions after two years of daily vosoritide treatment, a new study analysis finds. Results of the industry-sponsored study will be presented at ENDO 2021, the Endocrine Society's annual meeting.
"This is the first robust evidence of a precision therapy for achondroplasia," said the lead investigator, Ravi Savarirayan, M.D., Ph.D., a professor at Murdoch Children's Research Institute at Royal Children's Hospital in Parkville, Australia.
Achondroplasia is a genetic bone growth ...
2021-03-20
WASHINGTON--A study in mice finds treatment with a molecule called MCB-613 repairs heart tissue after a severe heart attack, preventing damage that can lead to heart failure. The findings are being presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
"This is a remarkable discovery that may lead to effective and safe treatments to prevent the progression to heart failure after a heart attack," said lead researcher Lisa K. Mullany, Ph.D., of Baylor College of Medicine in Houston.
Heart failure after a heart attack is the leading cause of death in humans, and currently there are no definitive therapies other than heart transplantation.
Researchers had previously found that MCB-613 stimulates proteins called steroid receptor coactivators ...
2021-03-20
WASHINGTON--Children with adrenal insufficiency--a condition in which the adrenal gland does not function properly--are at more than 10 times higher risk for COVID-19 complications and death compared with children with normal adrenal glands, according to a study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
Adrenal insufficiency is a disorder that occurs when the adrenal glands, located just above the kidneys, don't make enough of the hormone cortisol. The primary form of adrenal insufficiency is also called Addison's disease. Known as the "stress ...
LAST 30 PRESS RELEASES:
[Press-News.org] Common drugs for type 2 diabetes and obesity do not increase breast cancer risk
Findings relieve concerns arising from clinical trials of liraglutide
